DR Congo Launches Ebola Vaccine Trials for Frontline Health Workers

The Democratic Republic of Congo is quietly rolling out its first Ebola vaccine trial in more than a decade, targeting the very people who are on the front lines of the country’s latest health crisis – doctors, nurses, laboratory technicians and community health volunteers.

Officials say the experimental programme will use the Ervebo vaccine, the same shot that helped bring past outbreaks under control in North Kivu and Ituri provinces. That vaccine has already earned WHO pre‑qualification, but this is the first time it’s being tested against the new strain that sparked the recent surge of cases.

In practice, the rollout looks simple: a handful of health centres in the eastern town of Beni will receive vials of the frozen‑dot‑pen, health workers will be screened, given a dose and then monitored for side‑effects over the next 30 days. The plan calls for about 300 volunteers, split evenly between nurses and physicians, with a second wave slated for August if early results look promising.

"We owe it to the people who risk their lives every day," said Dr. Jean‑Claude Mbutu, the provincial health director, during a brief press briefing. "If the vaccine works, it could become the first line of defence for anyone caring for patients in remote clinics." He added that the trial will be overseen by a joint team of Congolese and international epidemiologists, ensuring data are collected transparently.

Logistics remain a hurdle, though. Cold‑chain equipment has to travel over rough, sometimes insecure roads, and there are lingering doubts among some staff about receiving a relatively new vaccine. Yet the urgency of the outbreak – which has already claimed dozens of lives and left hospitals scrambling – appears to outweigh the hesitations.

Beyond the immediate goal of protecting health workers, the trial could set a precedent for rapid vaccine deployment across the region. Success here might convince other African nations to adopt similar strategies, turning a painful chapter of fear into a stepping stone toward stronger, vaccine‑ready health systems.